nach oben

Current Addiction Reports

Erschienen in:

01.09.2022 | Cannabis (B Sherman and R Tomko, Section Editors)

Cannabis and Pregnancy: Factors Associated with Cannabis Use Among Pregnant Women and the Consequences for Offspring Neurodevelopment and Early Postpartum Parenting Behavior

verfasst von: Tessa L. Crume, Shannon Powers, Alexander J. Dufford, Pilyoung Kim

Erschienen in: Current Addiction Reports | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

To provide a narrative summary of the epidemiology of prenatal cannabis use, the known reasons for use, the effects of in utero cannabis exposure on offspring neurodevelopment and impact on mother-infant attachment.

Recent findings

Compelling evidence from human imaging studies suggest that in utero cannabis exposure disrupts early brain development and has long-term behavioral consequences for the offspring. Maternal postpartum cannabis use may diminish the maternal-infant bonding process and quality of caregiving.

Summary

The combination of increasing trends in prenatal cannabis use, low perceived risk, and increasing potency pose a serious challenge for the clinical and public health communities. Additional research is needed to understand the consequences of in utero exposure as well as postnatal maternal impacts that diminish the quality of caregiving. Most importantly, clinical cessation programs are needed to support women who enter pregnancy with cannabis dependency.

Agrawal A, Rogers CE, Lessov-Schlaggar CN, Carter EB, Lenze SN, Grucza RA. Alcohol, Cigarette, and Cannabis Use Between 2002 and 2016 in pregnant women from a nationally representative sample. JAMA Pediatr. 2019;173(1):95–6.PubMedCrossRef

Crume TL, Juhl AL, Brooks-Russell A, Hall KE, Wymore E, Borgelt LM. Cannabis use during the perinatal period in a state with legalized recreational and medical marijuana: the association between maternal characteristics, breastfeeding patterns, and neonatal outcomes. J Pediatr. 2018;197:90–6.PubMedCrossRef

Young-Wolff KC, Sarovar V, Tucker LY, Avalos LA, Alexeeff S, Conway A, et al. Trends in marijuana use among pregnant women with and without nausea and vomiting in pregnancy, 2009–2016. Drug Alcohol Depend. 2019;196:66–70.PubMedPubMedCentralCrossRef

Brown QL, Sarvet AL, Shmulewitz D, Martins SS, Wall MM, Hasin DS. Trends in marijuana use among pregnant and nonpregnant reproductive-aged women, 2002–2014. JAMA. 2017;317(2):207–9.PubMedPubMedCentralCrossRef

Allen AM, Jung AM, Alexander AC, Allen SS, Ward KD, al’Absi M. Cannabis use and stressful life events during the perinatal period: cross-sectional results from Pregnancy Risk Assessment Monitoring System (PRAMS) data, 2016. Addiction. 2020;115(9):1707–16.PubMedPubMedCentralCrossRef

Alshaarawy O, Anthony JC. Cannabis use among women of reproductive age in the United States: 2002–2017. Addict Behav. 2019;99:106082.PubMedPubMedCentralCrossRef

Roberson EK, Patrick WK, Hurwitz EL. Marijuana use and maternal experiences of severe nausea during pregnancy in Hawai’i. Hawaii J Med Public Health. 2014;73(9):283–7.PubMedPubMedCentral

van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N, et al. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend. 2010;109(1–3):243–7.PubMedCrossRef

• Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, Calvigioni D, et al. Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J. 2014;33(7):668–85. This study demonstrated that exogenous THC exposure during fetal development can trigger a endogenous cannabiniod-receptor-driven molecular cascade that disrupts neuronal specification and rewires fetal cortical circuitry. The authors identified a substrate of altered neuronal connectivity due to THC exposure, Superior Cervical Ganglion 10 (SCG10)/stathmin-2, a microtubule-binding protein in axons. SCG10 mRNA and protein was found to be reduced in the hippocampus of midgestational human cannabis-exposed fetuses, defining SCG10 as the first cannabis-driven molecular effector in the developing cerebrum. CB1 cannabinoid receptor activation by exogenous cannabioniods (THC) recruited in c-Jun N-terminal kinases to phosphorylate SCG10, promoting its rapid degradation in situ in motile axons and microtubule stabilization. Thus, THC enables ectopic formation of filopodia and alters axon morphology.

10.

Association AP. Diagnostic and Statistical manual of mental disorders. 1994.

11.

ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9.PubMedPubMedCentralCrossRef

12.

ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF 3rd. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980–1997. J Forensic Sci. 2000;45(1):24–30.PubMedCrossRef

13.

Monte AA, Zane RD, Heard KJ. The implications of marijuana legalization in Colorado. JAMA. 2015;313(3):241–2.PubMedPubMedCentralCrossRef

14.

Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585–614.PubMedCrossRef

15.

Foster BC, Abramovici H, Harris CS. Cannabis and cannabinoids: kinetics and interactions. Am J Med. 2019;132(11):1266–70.PubMedCrossRef

16.

Lozano J, Garcia-Algar O, Vall O, de la Torre R, Scaravelli G, Pichini S. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit. 2007;29(6):711–34.PubMedCrossRef

17.

Koren G, Chan D, Klein J, Karaskov T. Estimation of fetal exposure to drugs of abuse, environmental tobacco smoke, and ethanol. Ther Drug Monit. 2002;24(1):23–5.PubMedCrossRef

18.

Ostrea EM Jr, Parks PM, Brady MJ. Rapid isolation and detection of drugs in meconium of infants of drug-dependent mothers. Clin Chem. 1988;34(11):2372–3.PubMedCrossRef

19.

Moore C, Negrusz A, Lewis D. Determination of drugs of abuse in meconium. J Chromatogr B Biomed Sci Appl. 1998;713(1):137–46.PubMedCrossRef

20.

Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614–48.PubMedCrossRef

21.

Dreher MC, Nugent K, Hudgins R. Prenatal marijuana exposure and neonatal outcomes in Jamaica: an ethnographic study. Pediatrics. 1994;93(2):254–60.PubMedCrossRef

22.

Committee Opinion No. 722: Marijuana use during pregnancy and lactation. Obstet Gynecol. 2017;130(4):e205–9.CrossRef

23.

Mark K, Gryczynski J, Axenfeld E, Schwartz RP, Terplan M. Pregnant women’s current and intended cannabis use in relation to their views toward legalization and knowledge of potential harm. J Addict Med. 2017;11(3):211–6.PubMedCrossRef

24.

Jarlenski M, Tarr JA, Holland CL, Farrell D, Chang JC. Pregnant women’s access to information about perinatal marijuana use: a qualitative study. Womens Health Issues. 2016;26(4):452–9.PubMedPubMedCentralCrossRef

25.

Weisbeck SJ, Bright KS, Ginn CS, Smith JM, Hayden KA, Ringham C. Perceptions about cannabis use during pregnancy: a rapid best-framework qualitative synthesis. Can J Public Health. 2021;112(1):49–59.PubMedCrossRef

26.

Bayrampour H, Zahradnik M, Lisonkova S, Janssen P. Women’s perspectives about cannabis use during pregnancy and the postpartum period: an integrative review. Prev Med. 2019;119:17–23.PubMedCrossRef

27.

Dickson B, Mansfield C, Guiahi M, Allshouse AA, Borgelt LM, Sheeder J, et al. Recommendations from cannabis dispensaries about first-trimester cannabis use. Obstet Gynecol. 2018;131(6):1031–8.PubMedPubMedCentralCrossRef

28.

Richards JR. Cannabinoid hyperemesis syndrome: pathophysiology and treatment in the emergency department. J Emerg Med. 2018;54(3):354–63.PubMedCrossRef

29.

Committee on Practice B-O. ACOG practice bulletin no. 189: Nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131(1):e15-e30.

30.

Gaynes BN, Gavin N, Meltzer-Brody S, Lohr KN, Swinson T, Gartlehner G, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005;119:1–8.

31.

Ko JY, Tong VT, Bombard JM, Hayes DK, Davy J, Perham-Hester KA. Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: a population-based study. Drug Alcohol Depend. 2018;187:72–8.PubMedPubMedCentralCrossRef

32.

Goodwin RD, Zhu J, Heisler Z, Metz TD, Wyka K, Wu M, et al. Cannabis use during pregnancy in the United States: the role of depression. Drug Alcohol Depend. 2020;210: 107881.PubMedCrossRef

33.

LeTendre ML, Reed MB. The effect of adverse childhood experience on clinical diagnosis of a substance use disorder: results of a nationally representative study. Subst Use Misuse. 2017;52(6):689–97.PubMedPubMedCentralCrossRef

34.

al'Absi M, Lemieux A, Westra R, Allen S. Early life adversity influences stress response association with smoking relapse. Psychopharmacology (Berl). 2017;234(22):3375–84.

35.

Hirschtritt ME, Avalos LA, Sarovar V, Ridout KK, Goler NC, Ansley DR, et al. Association between prenatal cannabis use and psychotropic medication use in pregnant patients with depression and anxiety. J Addict Med. 2022.

36.

Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health. 2005;8(4):214–20.PubMedCrossRef

37.

Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? Neuropsychiatr Dis Treat. 2013;9:1257–66.PubMedPubMedCentralCrossRef

38.

Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49(11):726–35.PubMedCrossRef

39.

Davalos DB, Yadon CA, Tregellas HC. Untreated prenatal maternal depression and the potential risks to offspring: a review. Arch Womens Ment Health. 2012;15(1):1–14.PubMedCrossRef

40.

Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev. 2006;29(3):445–55.PubMedCrossRef

41.

Bara A, Ferland JN, Rompala G, Szutorisz H, Hurd YL. Cannabis and synaptic reprogramming of the developing brain. Nat Rev Neurosci. 2021;22(7):423–38.PubMedPubMedCentralCrossRef

42.

Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316(5828):1212–6.PubMedCrossRef

43.

Mulder J, Aguado T, Keimpema E, Barabas K, Ballester Rosado CJ, Nguyen L, et al. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci U S A. 2008;105(25):8760–5.PubMedPubMedCentralCrossRef

44.

Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(Suppl 1):S163–71.PubMedPubMedCentralCrossRef

45.

Grant KS, Petroff R, Isoherranen N, Stella N, Burbacher TM. Cannabis use during pregnancy: Pharmacokinetics and effects on child development. Pharmacol Ther. 2018;182:133–51.PubMedCrossRef

46.

Jutras-Aswad D, DiNieri JA, Harkany T, Hurd YL. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):395–412.PubMedCrossRef

47.

Castaldo P, Magi S, Cataldi M, Arcangeli S, Lariccia V, Nasti AA, et al. Altered regulation of glutamate release and decreased functional activity and expression of GLT1 and GLAST glutamate transporters in the hippocampus of adolescent rats perinatally exposed to Delta(9)-THC. Pharmacol Res. 2010;61(4):334–41.PubMedCrossRef

48.

Shum C, Dutan L, Annuario E, Warre-Cornish K, Taylor SE, Taylor RD, et al. Delta(9)-tetrahydrocannabinol and 2-AG decreases neurite outgrowth and differentially affects ERK1/2 and Akt signaling in hiPSC-derived cortical neurons. Mol Cell Neurosci. 2020;103: 103463.PubMedCrossRef

49.

Saez TM, Aronne MP, Caltana L, Brusco AH. Prenatal exposure to the CB1 and CB2 cannabinoid receptor agonist WIN 55,212–2 alters migration of early-born glutamatergic neurons and GABAergic interneurons in the rat cerebral cortex. J Neurochem. 2014;129(4):637–48.PubMedCrossRef

50.

Grant KS, Conover E, Chambers CD. Update on the developmental consequences of cannabis use during pregnancy and lactation. Birth Defects Res. 2020;112(15):1126–38.PubMedPubMedCentralCrossRef

51.

Huizink AC. Prenatal cannabis exposure and infant outcomes: overview of studies. Prog Neuropsychopharmacol Biol Psychiatry. 2014;52:45–52.PubMedCrossRef

52.

Thomason ME, Palopoli AC, Jariwala NN, Werchan DM, Chen A, Adhikari S, et al. Miswiring the brain: Human prenatal Delta9-tetrahydrocannabinol use associated with altered fetal hippocampal brain network connectivity. Dev Cogn Neurosci. 2021;51: 101000.PubMedPubMedCentralCrossRef

53.

•• Grewen K, Salzwedel AP, Gao W. Functional connectivity disruption in neonates with prenatal marijuana exposure. Front Hum Neurosci. 2015;9:601. The authors investigated the effects of prenatal marijuana on development of early brain functional circuitry prior to prolonged postnatal environmental influences by measuring resting state functional connectivity during unsedated sleep in infants at 2–6 weeks. Imaging analyses focused on connectivity of subcortical seed regions with high fetal CB1R expression. Marijuana-specific differences were observed in insula and three striatal connections: anterior insula-cerebellum, right caudate-cerebellum, right caudate-right fusiform gyrus/inferior occipital, left caudate-cerebellum. The marijuana exposed neonates were found to have hypo-connectivity in all clusters compared non-exposed neonates. Altered striatal connectivity to areas involved in visual spatial and motor learning, attention, and in fine-tuning of motor outputs involved in movement and language production may contribute to neurobehavioral deficits.

54.

El Marroun H, Tiemeier H, Franken IH, Jaddoe VW, van der Lugt A, Verhulst FC, et al. Prenatal Cannabis and tobacco exposure in relation to brain morphology: a prospective neuroimaging study in young children. Biol Psychiatry. 2016;79(12):971–9.PubMedCrossRef

55.

Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77(2):299–318.PubMedCrossRef

56.

Wang X, Dow-Edwards D, Keller E, Hurd YL. Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience. 2003;118(3):681–94.PubMedCrossRef

57.

Antonelli T, Tomasini MC, Tattoli M, Cassano T, Tanganelli S, Finetti S, et al. Prenatal exposure to the CB1 receptor agonist WIN 55,212–2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring. Cereb Cortex. 2005;15(12):2013–20.PubMedCrossRef

58.

Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol Teratol. 2004;26(4):533–42.PubMedCrossRef

59.

Hoekzema E, Barba-Muller E, Pozzobon C, Picado M, Lucco F, Garcia-Garcia D, et al. Pregnancy leads to long-lasting changes in human brain structure. Nat Neurosci. 2017;20(2):287–96.PubMedCrossRef

60.

Kim P, Leckman JF, Mayes LC, Feldman R, Wang X, Swain JE. The plasticity of human maternal brain: longitudinal changes in brain anatomy during the early postpartum period. Behav Neurosci. 2010;124(5):695–700.PubMedPubMedCentralCrossRef

61.

Strathearn L, Li J, Fonagy P, Montague PR. What’s in a smile? Maternal brain responses to infant facial cues. Pediatrics. 2008;122(1):40–51.PubMedCrossRef

62.

Swain JE, Lorberbaum JP, Kose S, Strathearn L. Brain basis of early parent-infant interactions: psychology, physiology, and in vivo functional neuroimaging studies. J Child Psychol Psychiatry. 2007;48(3–4):262–87.PubMedPubMedCentralCrossRef

63.

Brunton PJ, Russell JA. The expectant brain: adapting for motherhood. Nat Rev Neurosci. 2008;9(1):11–25.PubMedCrossRef

64.

Brunton PJ, Russell JA. Endocrine induced changes in brain function during pregnancy. Brain Res. 2010;1364:198–215.PubMedCrossRef

65.

Russell JA, Douglas AJ, Ingram CD. Brain preparations for maternity–adaptive changes in behavioral and neuroendocrine systems during pregnancy and lactation. An overview. Prog Brain Res. 2001;133:1–38.PubMedCrossRef

66.

Barba-Muller E, Craddock S, Carmona S, Hoekzema E. Brain plasticity in pregnancy and the postpartum period: links to maternal caregiving and mental health. Arch Womens Ment Health. 2019;22(2):289–99.PubMedCrossRef

67.

Rutherford HJ, Wallace NS, Laurent HK, Mayes LC. Emotion regulation in parenthood. Dev Rev. 2015;36:1–14.PubMedPubMedCentralCrossRef

68.

Bayazit H, Selek S, Karababa IF, Cicek E, Aksoy N. Evaluation of oxidant/antioxidant status and cytokine levels in patients with cannabis use disorder. Clin Psychopharmacol Neurosci. 2017;15(3):237–42.PubMedPubMedCentralCrossRef

69.

Saroz Y, Kho DT, Glass M, Graham ES, Grimsey NL. Cannabinoid receptor 2 (CB2) signals via G-alpha-s and induces IL-6 and IL-10 cytokine secretion in human primary leukocytes. ACS Pharmacol Transl Sci. 2019;2(6):414–28.PubMedPubMedCentralCrossRef

70.

Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20(Suppl 1):10–4.PubMedCrossRef

71.

Kim P, Feldman R, Mayes LC, Eicher V, Thompson N, Leckman JF, et al. Breastfeeding, brain activation to own infant cry, and maternal sensitivity. J Child Psychol Psychiatry. 2011;52(8):907–15.PubMedPubMedCentralCrossRef

72.

Musser ED, Kaiser-Laurent H, Ablow JC. The neural correlates of maternal sensitivity: an fMRI study. Dev Cogn Neurosci. 2012;2(4):428–36.PubMedPubMedCentralCrossRef

73.

Rutherford HJ, Gerig G, Gouttard S, Potenza MN, Mayes LC. Investigating maternal brain structure and its relationship to substance use and motivational systems. Yale J Biol Med. 2015;88(3):211–7.PubMedPubMedCentral

74.

Eiden RD, Schuetze P, Shisler S, Huestis MA. Prenatal exposure to tobacco and cannabis: effects on autonomic and emotion regulation. Neurotoxicol Teratol. 2018;68:47–56.PubMedPubMedCentralCrossRef

75.

Feldman R. The neurobiology of human attachments. Trends Cogn Sci. 2017;21(2):80–99.PubMedCrossRef

76.

Schuler ME, Nair P, Black MM. Ongoing maternal drug use, parenting attitudes, and a home intervention: effects on mother-child interaction at 18 months. J Dev Behav Pediatr. 2002;23(2):87–94.PubMedPubMedCentralCrossRef

77.

Abel EL, Tan SE, Subramanian M. Effects of delta 9-tetrahydrocannabinol, phenobarbital, and their combination on pregnancy and offspring in rats. Teratology. 1987;36(2):193–8.PubMedCrossRef

78.

•• Hill M, Sternberg A, Suk HW, Meier MH, Chassin L. The intergenerational transmission of cannabis use: associations between parental history of cannabis use and cannabis use disorder, low positive parenting, and offspring cannabis use. Psychol Addict Behav. 2018;32(1):93–103. The authors prospectively evaluated a metric of low positive parenting as a mediator of the relation between parental cannabis use and adolescent cannabis use at the family level and individual level. They found that parental cannabis use disorder was associated with adolescent cannabis use predicted low positive parenting. Average levels of low positive parenting within a family partially mediated the association between parental cannabis use disorder and offspring cannabis use. Results suggest that average levels of positive parenting in families may be a mechanism underlying the intergenerational transmission of cannabis use.

79.

Chamberlain C, O'Mara-Eves A, Porter J, Coleman T, Perlen SM, Thomas J, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev. 2017;2:CD001055.

Titel: Cannabis and Pregnancy: Factors Associated with Cannabis Use Among Pregnant Women and the Consequences for Offspring Neurodevelopment and Early Postpartum Parenting Behavior
verfasst von: Tessa L. Crume
Shannon Powers
Alexander J. Dufford
Pilyoung Kim
Publikationsdatum: 01.09.2022
Verlag: Springer International Publishing
Erschienen in: Current Addiction Reports / Ausgabe 3/2022
Elektronische ISSN: 2196-2952
DOI: https://doi.org/10.1007/s40429-022-00419-6

Neu im Fachgebiet Psychiatrie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cannabis and Pregnancy: Factors Associated with Cannabis Use Among Pregnant Women and the Consequences for Offspring Neurodevelopment and Early Postpartum Parenting Behavior